Mortality reduction in pediatric patients with severe fatal human adenoviral pneumonia treated with high titer neutralizing antibodies (NAbs) plasma: a retrospective cohort study

Table 3 Risk factors for mortality in patients with severe fatal human adenoviral pneumonia

Variables	Univariable analysis			Multivariable analysis
Variables	OR	95%CI	P	OR	95%CI	P
SOFA score (.<7 versus ≥7)	8.400	2.076–33.982	0.003	7.686	1.735–34.054	0.007
OI (.<8 versus ≥8)	2.955	0.827–10.561	0.096	3.721	0.789–17.550	0.097
High titer NAbs plasma treatment (yes versus no)	3.300	1.016–10.719	0.047	4.298	1.030–17.934	0.045

ISSN: 1471-2431